Compare AT&T Inc. (T) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs TransMedics Group Inc — how do they compare? AT&T Inc. trades at $24.29 (market cap $167.88B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: AT&T Inc. is far larger — about 54.2× TransMedics Group Inc's market cap, and AT&T Inc. pays a 4.53% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| T | TMDX | |
|---|---|---|
Market Cap | $167.88B | $3.10B |
Sector | Media | Technology |
52-Week High | $29.62 | $150.42 |
52-Week Low | $20.49 | $61.99 |
Enterprise Value | $313.20B | $3.49B |
Dividend Yield | 4.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.25, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI near 77. The stock shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights fiber expansion and AI partnerships, while cash flow improved to $15.12B in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14% upside, supported by dividend yield near 4.7%. Risks include competition from SpaceX's Starlink and high debt levels. Analysts are mixed with 41% buy ratings, suggesting cautious optimism for value investors seeking income and steady growth.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
